ADMP - Adamis Pharmaceuticals Corporation Stock Price, Fair Value and News

Delayed

ADMP Stock Price

View Fullscreen

ADMP RSI Chart

ADMP Valuation

Market Cap

8.0M

Price/Earnings (Trailing)

-0.36

Price/Sales (Trailing)

2.21

EV/EBITDA

-0.05

Price/Free Cashflow

-0.85

ADMP Price/Sales (Trailing)

ADMP Profitability

EBT Margin

-723.75%

Return on Equity

-6.99%

Return on Assets

-248.2%

Free Cashflow Yield

-117.33%

ADMP Fundamentals

ADMP Revenue

Revenue (TTM)

3.6M

Rev. Growth (Yr)

-99.4%

Rev. Growth (Qtr)

30.48%

ADMP Earnings

Earnings (TTM)

-22.2M

Earnings Growth (Yr)

68.45%

Earnings Growth (Qtr)

83.81%

Breaking Down ADMP Revenue

Last 7 days

-4.4%

Last 30 days

-44.7%

Last 90 days

-61.8%

Trailing 12 Months

137.5%

How does ADMP drawdown profile look like?

ADMP Financial Health

Current Ratio

0.58

ADMP Investor Care

Shares Dilution (1Y)

371.48%

Diluted EPS (TTM)

-9.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	5.1M	5.1M	3.6M	0
2022	2.9M	3.5M	4.2M	4.9M
2021	6.9M	4.2M	4.1M	2.2M
2020	21.9M	20.0M	15.0M	10.1M
2019	16.8M	18.7M	20.7M	22.1M
2018	13.2M	13.3M	13.8M	15.1M
2017	8.1M	9.8M	11.4M	13.1M
2016	0	0	0	6.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Adamis Pharmaceuticals Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 25, 2023	versi jannine	acquired	-	-	177,194	-
May 25, 2023	versi ebrahim	acquired	-	-	8,745	ceo
May 25, 2023	versi ebrahim	acquired	-	-	177,194	ceo
May 25, 2023	desai meera j.	acquired	-	-	3,138	-
May 25, 2022	carlo dennis j phd	acquired	-	-	250,000	-
Mar 18, 2022	benedicto david c.	sold	-2,207	0.6128	-3,603	chief financial officer
Mar 18, 2022	moss ronald b.	sold	-4,948	0.6036	-8,199	chief medical officer
Mar 18, 2022	marguglio david j.	sold	-7,116	0.6001	-11,859	svp and chief business officer
Mar 18, 2022	carlo dennis j phd	sold	-6,286	0.5993	-10,490	president & ceo
Dec 09, 2021	marguglio david j.	gifted	-	-	-13,000	svp of bus. dev & cbo

Which funds bought or sold ADMP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Clear Point Advisors Inc.	unchanged	-	-34.00	3.00	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-935	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-392	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-45,642	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-12,647	-	-%
May 14, 2024	OLD POINT TRUST & FINANCIAL SERVICES N A	new	-	1.00	1.00	-%
May 14, 2024	Winch Advisory Services, LLC	unchanged	-	-1.00	-	-%
May 14, 2024	NewEdge Advisors, LLC	sold off	-100	-27.00	-	-%
May 14, 2024	NORTHERN TRUST CORP	sold off	-100	-72,476	-	-%
May 13, 2024	FMR LLC	sold off	-100	-1.00	-	-%

Are Funds Buying or Selling ADMP?

Are funds buying ADMP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADMP

No. of Funds

Unveiling Adamis Pharmaceuticals Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	intracoastal capital, llc	6.0%	650,000	SC 13G/A
Sep 26, 2023	versi group llc	989%	1,018,024	SC 13D/A
Aug 10, 2023	intracoastal capital, llc	7.6%	650,000	SC 13G
Jun 05, 2023	versi group llc	9.99%	288,824	SC 13D
Feb 16, 2021	cvi investments, inc.	4.9%	4,918,972	SC 13G/A
Feb 28, 2020	cvi investments, inc.	7.9%	5,800,000	SC 13G
Feb 13, 2020	683 capital management, llc	2.8%	1,750,000	SC 13D/A
Feb 13, 2020	683 capital management, llc	2.8%	1,750,000	SC 13G/A
Feb 10, 2020	cvi investments, inc.	4.6%	3e+06	SC 13G/A
Feb 04, 2020	first manhattan co	0.00%	0	SC 13G/A

Recent SEC filings of Adamis Pharmaceuticals Corporation

View All Filings

Date Filed	Form Type	Document
Mar 21, 2024	25-NSE	25-NSE

Adamis Pharmaceuticals Corporation News

Latest updates

Adamis Pharmaceuticals Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	30.5%	9,062	6,945	1,453,000	2,150,682	1,505,683	39,847	1,154,514	957,238	759,962	1,275,474	1,393,097	679,791	868,077	3,926,342	4,663,210	5,540,223	5,902,975	5,764,899	4,905,772	4,153,907	3,832,935
Gross Profit	7.1%	-329,426	-354,449	-335,066	-331,107	-141,902	-649,331	-309,068	-2,854,373	-805,960	-520,769	-452,140	-1,941,478	-546,009	-757,493	976,166	1,341,403	1,914,013	2,099,334	1,280,303	1,113,908	1,532,503
S&GA Expenses	-37.6%	2,517,161	4,033,083	4,782,086	3,150,788	2,508,176	4,205,934	3,382,696	2,896,558	4,794,485	4,934,491	3,518,052	7,771,335	3,308,686	5,653,092	6,054,371	4,965,657	5,300,107	7,000,339	8,021,464	6,576,571	6,534,745
R&D Expenses	-	-	-	1,310,529	859,846	1,977,939	3,320,654	4,221,525	2,195,765	4,620,143	2,196,721	2,249,744	1,349,332	1,647,746	3,085,824	2,036,732	2,014,989	3,318,743	2,845,745	2,196,514	7,800,725	3,908,408
EBITDA Margin	-43.2%	-7.06	-4.93	-4.84	-5.09	-7.90	-9.39	-11.55	-15.01	-8.44	-8.10	-4.90	-3.26	-1.60	-1.20	-	-	-	-	-	-	-
Interest Expenses	-36.4%	29,465	46,312	-	-	-	-	-	-	1,865	2,900	1,884	-33,152	1,722	32,925	38,287	54,361	21,935	22,954	24,008	25,010	30,653
Income Taxes	-	-	-	-	-1,625	-	-	-	-	-	-	-	-8,900	-	-	-	-1,045	105	-	-	-377,990	-
Earnings Before Taxes	-	-	-	-9,014,608	-3,400,989	-4,271,209	-	-10,189,754	-7,811,910	-5,168,406	-	-	-11,869,093	-10,001,983	-	-	-	-	-	-	-	-
EBT Margin	-41.3%	-7.24	-5.12	-5.09	-5.40	-8.26	-9.80	-12.06	-15.67	-8.72	-8.50	-5.22	-3.54	-1.83	-1.37	-	-	-	-	-	-	-
Net Income	83.8%	-1,388,046	-8,574,122	-8,942,907	-3,327,536	-4,398,901	-8,397,221	-10,354,615	-8,774,186	-12,361,048	-9,313,730	-15,379,234	-17,858,809	-11,361,198	-12,924,713	-7,246,369	-3,890,126	-6,999,751	-7,735,587	-8,887,305	-12,810,757	-8,875,283
Net Income Margin	-24.5%	-6.14	-4.93	-4.87	-5.46	-7.62	-11.30	-14.22	-20.75	-13.37	-12.79	-8.38	-4.87	-2.36	-1.55	-	-	-	-	-	-	-
Free Cashflow	-40.5%	-3,737,240	-2,660,028	-1,639,032	-1,613,537	-7,705,834	-10,248,888	-7,012,664	-6,900,825	-9,915,818	-17,249,854	-4,942,249	-5,381,080	-5,929,796	-5,526,706	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	88.6%	9.00	5.00	9.00	11.00	12.00	18.00	31.00	38.00	45.00	64.00	81.00	31.00	44.00	31.00	45.00	48.00	53.00	47.00	53.00	58.00	70.00
Current Assets	128.1%	8.00	3.00	8.00	9.00	10.00	15.00	28.00	35.00	42.00	46.00	63.00	13.00	17.00	12.00	15.00	14.00	18.00	12.00	17.00	26.00	38.00
Cash Equivalents	940.8%	7.00	1.00	3.00	1.00	2.00	9.00	18.00	23.00	29.00	40.00	58.00	7.00	12.00	8.00	11.00	9.00	12.00	4.00	9.00	19.00	32.00
Inventory	-0.2%	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	-	2.00	3.00	1.00	2.00	2.00	3.00	2.00	3.00	3.00	3.00	3.00	3.00
Net PPE	-5.9%	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	10.00	10.00	2.00	11.00	11.00	11.00	12.00	12.00	12.00	11.00	10.00	9.00
Goodwill	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	4.00	4.00	4.00	8.00	8.00	8.00	8.00	8.00	8.00
Liabilities	-14.3%	14.00	16.00	19.00	12.00	9.00	11.00	15.00	12.00	11.00	17.00	25.00	27.00	23.00	20.00	14.00	15.00	13.00	13.00	13.00	12.00	12.00
Current Liabilities	-10.3%	13.00	15.00	13.00	11.00	9.00	10.00	14.00	11.00	9.00	13.00	21.00	20.00	12.00	12.00	11.00	9.00	11.00	11.00	11.00	12.00	12.00
Shareholder's Equity	-	-	-	-	-	3.00	7.00	16.00	26.00	34.00	47.00	55.00	6.00	20.00	20.00	31.00	33.00	40.00	34.00	40.00	47.00	58.00
Retained Earnings	-0.4%	-323	-322	-313	-304	-301	-296	-288	-278	-269	-256	-247	-229	-212	-200	-187	-180	-176	-169	-161	-153	-140
Additional Paid-In Capital	2.6%	318	310	304	304	304	304	304	304	304	304	303	233	233	221	219	214	217	203	202	200	198
Shares Outstanding	261.8%	10.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	74.00	-	-	-	163	-	-	-	39.00	-	-	-	61.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	-45.5%	-3,737	-2,568	-1,547	-1,522	-7,498	-9,894	-6,985	-6,673	-9,766	-16,808	-4,536	-5,411	-6,109	-5,140	-4,239	-2,938	-4,257	-4,416	-8,273	-12,275	-7,981
Share Based Compensation	-185.6%	-44.69	52.00	69.00	-325	76.00	-464	372	551	153	1.00	880	1,214	829	292	1,219	2,210	9.00	882	1,978	3,194	-
Cashflow From Investing	1178.0%	1,767	138	842	155	779	1,017	1,533	1,165	-34.63	-441	-406	18.00	-53.91	-636	-274	-301	-361	-538	-1,665	-364	-1,900
Cashflow From Financing	1061690.1%	7,963	750*	2,724	-	-	-	-	-42.85	-2,007	-24.79	56,011	-128	10,649	3,162	6,210	-71.73	12,648	-143	-141	-122	37,495

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ADMP Income Statement

2023-06-30

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)

3 Months Ended

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

Income Statement [Abstract]

REVENUE, net

$ 6,945

$ 39,847

$ 1,459,945

$ 1,194,361

COST OF GOODS SOLD

361,394

689,178

2,149,461

2,152,760

Gross Loss

(354,449)

(649,331)

(689,516)

(958,399)

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

4,033,083

4,205,934

8,815,168

7,588,630

RESEARCH AND DEVELOPMENT

376,957

3,320,654

1,687,486

7,542,179

ACQUIRED IN-PROCESS RESEARCH & DEVELOPMENT (IPR&D)

6,539,675

Loss from Operations

(11,304,164)

(8,175,919)

(17,731,845)

(16,089,208)

OTHER INCOME (EXPENSE)

Interest Income

703

16,174

713

20,322

Interest Expense

(46,312)

(106,344)

Other Income/(Expense)

463,018

(257,832)

410,017

(697,832)

Gain/(Loss) on PPP2 loan

62,583

(1,787,417)

Excess of March 2023 Warrant Fair Value over Offering Proceeds

(2,476,109)

Change in Fair Value of Warrants

3,883,364

19,540

3,885,569

28,927

Total Other Income (Expense), net

4,300,773

(159,535)

1,713,846

(2,436,000)

Net Loss from Continuing Operations

(7,003,391)

(8,335,454)

(16,017,999)

(18,525,208)

DISCONTINUED OPERATIONS

Net Loss from Discontinued Operations before Income Taxes

(1,570,731)

(61,767)

(1,499,030)

(226,628)

Income Taxes - Discontinued Operations

Net Loss from Discontinued Operations

(1,570,731)

(61,767)

(1,499,030)

(226,628)

Net Loss Applicable to Common Stock

$ (8,574,122)

$ (8,397,221)

$ (17,517,029)

$ (18,751,836)

Basic and Diluted Loss Per Share:

Continuing Operations, Basic Loss Per Share

^[1]

$ (2.79)

$ (3.89)

$ (6.81)

$ (8.66)

Continuing Operations, Diluted Loss Per Share

^[1]

(2.79)

(3.89)

(6.81)

(8.66)

Discontinued Operations, Basic Loss Per Share

^[1]

(0.61)

(0.03)

(0.63)

(0.11)

Discontinued Operations, Diluted Loss Per Share

^[1]

(0.61)

(0.03)

(0.63)

(0.11)

Basic Loss Per Share

^[1]

(3.40)

(3.92)

(7.44)

(8.77)

Diluted Loss Per Share

^[1]

$ (3.40)

$ (3.92)

$ (7.44)

$ (8.77)

Basic Weighted Average Shares Outstanding

^[1]

2,569,400

2,140,224

2,378,006

2,138,816

Diluted Weighted Average Shares Outstanding

^[1]

2,569,400

2,140,224

2,378,006

2,138,816

[1]	See Note 1, Reverse Stock Split

ADMP Balance Sheet

2023-06-30

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)

Jun. 30, 2023

Dec. 31, 2022

CURRENT ASSETS

Cash and Cash Equivalents (including $135,287 and $0 associated with variable interest entity at June 30, 2023 and December 31, 2022, respectively)

$ 640,254

$ 1,081,364

Restricted Cash

30,090

30,068

Accounts Receivable, net

1,054,058

Receivable from Fagron

18,971

30,951

Inventories

664,358

1,238,778

Prepaid Expenses and Other Current Assets

658,119

1,884,015

Current Assets of Discontinued Operations

1,438,906

3,952,916

Total Current Assets

3,450,698

9,272,150

LONG TERM ASSETS

Fixed Assets, net

1,142,869

1,288,894

Right-of-Use Assets

145,909

317,622

Other Non-Current Assets

9,674

52,174

Total Assets

4,749,150

10,930,840

CURRENT LIABILITIES

Accounts Payable

11,365,931

7,937,493

Deferred Revenue, current portion (including $147,118 and $0 associated with variable interest entity at June 30, 2023 and December 31, 2022, respectively)

174,897

27,779

Accrued Other Expenses

2,200,716

1,510,053

Product Recall Liability

175,190

305,806

Lease Liabilities, Current Portion

157,246

342,562

Current Liabilities of Discontinued Operations

933,246

1,272,173

Total Current Liabilities

15,007,226

11,395,866

LONG TERM LIABILITIES

Deferred Revenue, net of current portion

164,357

178,247

Warrant Liabilities, at fair value

1,072,893

7,492

Total Liabilities

16,244,476

11,581,605

MEZZANINE EQUITY

Convertible Preferred Stock - Par Value $0.0001; 10,000,000 Shares Authorized; Series C Preferred Stock 3,000 Shares Authorized, liquidation preference $110 per share; 3,000 Issued and Outstanding at June 30, 2023 and December 31, 2022, respectively

330,000

157,303

STOCKHOLDERS’ DEFICIT

Convertible Preferred Stock - Par Value $0.0001; 10,000,000 Shares Authorized; Series E Preferred Stock 1,941.2 Shares Authorized, Issued and Outstanding at June 30, 2023 and no Shares Authorized, Issued and Outstanding at December 31, 2022

Common Stock - Par Value $0.0001; 200,000,000 Shares Authorized; 2,797,865 and 2,150,051 Issued, 2,790,395 and 2,142,581 Outstanding at June 30, 2023 and December 31, 2022, respectively

^[1]

15,831

15,051

Additional Paid-in Capital

310,245,208

303,746,217

Accumulated Deficit

(322,081,115)

(304,564,086)

Treasury Stock - 7,470 Shares, at cost

^[1]

(5,250)

Total Stockholders’ Deficit

(11,825,326)

(808,068)

Total Liabilities, Mezzanine Equity and Stockholders’ Deficit

$ 4,749,150

$ 10,930,840

[1]	See Note 1, Reverse Stock Split

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation Frequently Asked Questions

What is the ticker symbol for Adamis Pharmaceuticals Corporation? What does ADMP stand for in stocks?

ADMP is the stock ticker symbol of Adamis Pharmaceuticals Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adamis Pharmaceuticals Corporation (ADMP)?

As of Tue Oct 31 2023, market cap of Adamis Pharmaceuticals Corporation is 7.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADMP stock?

You can check ADMP's fair value in chart for subscribers.

What is the fair value of ADMP stock?

You can check ADMP's fair value in chart for subscribers. The fair value of Adamis Pharmaceuticals Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adamis Pharmaceuticals Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADMP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adamis Pharmaceuticals Corporation a good stock to buy?

The fair value guage provides a quick view whether ADMP is over valued or under valued. Whether Adamis Pharmaceuticals Corporation is cheap or expensive depends on the assumptions which impact Adamis Pharmaceuticals Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADMP.

What is Adamis Pharmaceuticals Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 31 2023, ADMP's PE ratio (Price to Earnings) is -0.36 and Price to Sales (PS) ratio is 2.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADMP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Adamis Pharmaceuticals Corporation's stock?

In the past 10 years, Adamis Pharmaceuticals Corporation has provided -0.196 (multiply by 100 for percentage) rate of return.